Skip to content
Inciteful Med

Diagnosis & Biology: Making Sense of Your Results

Last updated:

Systemic Primary Carnitine Deficiency (SPCD) is initially detected by low free carnitine (C0) levels during newborn screening. Because a baby's levels can reflect the mother's, confirming the diagnosis requires testing the mother, SLC22A5 genetic sequencing, or a functional fibroblast study.

Key Takeaways

  • • SPCD is caused by mutations in the SLC22A5 gene, which impairs the OCTN2 protein responsible for pumping carnitine into cells.
  • • Newborn screening identifies potential SPCD by detecting abnormally low levels of free carnitine (C0) in the blood.
  • • A low carnitine level in a baby can sometimes be a reflection of the mother's own undiagnosed SPCD or secondary carnitine deficiency.
  • • Maternal testing is a mandatory step when investigating a positive newborn screen for SPCD.
  • • Diagnosis is confirmed using genetic sequencing of the SLC22A5 gene or a functional fibroblast uptake study.

Understanding the diagnosis of Systemic Primary Carnitine Deficiency (SPCD) requires looking at both the “blueprint” (your genes) and the “machinery” (how your body moves carnitine) [1]. While a positive newborn screen can be alarming, it is the first step in a process designed to ensure that if a deficiency exists, it is treated before it can cause harm [2][3].

The Biology: Genes and Transporters

At the heart of SPCD is the SLC22A5 gene. This gene provides the instructions for building a specialized protein called OCTN2 [4][1].

Think of OCTN2 as a high-speed “pump” located on the surface of your cells. Its job is to pull carnitine from the blood and move it into the cells [5][1]. Once inside, carnitine acts like a shuttle, carrying long-chain fats into the mitochondria to be burned for energy [6][7].

In SPCD, mutations in the SLC22A5 gene mean the OCTN2 pump is either missing or broken [4]. This leads to two major problems:

  1. Tissue Depletion: Organs like the heart and muscles cannot get the carnitine they need to create energy [5][1].
  2. Kidney Wasting: The kidneys normally “recycle” carnitine back into the blood; without a working pump, the carnitine is simply flushed out in the urine [1][8].

You can review a summary of these processes on The Basics page.

Newborn Screening (NBS): The First Clue

NBS looks for a marker called C0 (free carnitine) [3]. If the C0 level is below a certain cutoff—often less than 5–10 μ\mumol/L—it triggers a “red flag” for SPCD [9][10].

The NBS Pitfall: The Mother’s Role

A low carnitine level on a baby’s screen does not always mean the baby has the condition [11]. Because a baby gets their carnitine from their mother during pregnancy, a low result can sometimes be a “reflection” of the mother’s status [12][13]. This can happen if:

  • Maternal SPCD: The mother has the condition herself but was never diagnosed (common in adults) [14][15].
  • Maternal Diet or Health: The mother has a secondary deficiency due to pregnancy, diet, or other health factors [16][11].

Because of this overlap, testing the mother’s carnitine levels is a standard and necessary part of the baby’s diagnostic journey [13][15].

Mandatory Confirmatory Tests

Biochemical screening alone is never enough to confirm SPCD [11]. Two definitive tests are used to provide a final answer:

  1. Genetic Testing (SLC22A5 Sequencing): This looks directly at the DNA to find mutations [17][18]. SPCD is an autosomal recessive condition, meaning a person with SPCD will typically have two mutations (one inherited from each parent) [19].
  2. Functional Fibroblast Uptake Study: If genetic results are unclear (such as finding a “Variant of Uncertain Significance”), doctors may perform a skin biopsy to grow cells (fibroblasts) in a lab [12][20]. They then measure exactly how well those cells “pump” carnitine. This is the “gold standard” for seeing if the transporter is actually working [21][22].

Once a diagnosis is confirmed, establishing a Treatment Strategy is the next critical step.

Completeness Checklist

Ensure your medical team has evaluated all the following to confirm the diagnosis:

  • [ ] Newborn C0 Levels: Repeated plasma carnitine tests for the baby [11].
  • [ ] Maternal Testing: Carnitine levels and urine clearance tests for the mother [13][15].
  • [ ] Genetic Sequencing: Full sequencing of the SLC22A5 gene [14][18].
  • [ ] Acycarnitine Profile: A broader look at other fats in the blood to rule out other metabolic conditions [23][11].
  • [ ] Functional Study: (If needed) A fibroblast uptake test to confirm how the pumps are performing [12].

Frequently Asked Questions

Why did my baby's newborn screen show low carnitine?
A low free carnitine (C0) level on a newborn screen is an initial red flag for SPCD. However, because babies get their carnitine from their mothers during pregnancy, this low result can sometimes mean the mother has an undiagnosed deficiency rather than the baby.
Should a mother be tested if her baby has a positive SPCD screen?
Yes. Testing the mother's carnitine levels is a standard and necessary part of the diagnostic process. It helps doctors determine if the baby's low screening result is actually a reflection of the mother having undiagnosed SPCD or another health factor.
What is the purpose of SLC22A5 genetic testing?
The SLC22A5 gene provides the instructions for building the OCTN2 pump, which moves carnitine into your cells. Genetic testing looks directly at your DNA to find mutations in this gene, which helps confirm an SPCD diagnosis.
What happens if genetic testing for SPCD is unclear?
If genetic sequencing shows variants of uncertain significance, doctors may recommend a functional fibroblast uptake study. This involves taking a small skin biopsy to grow cells in a lab, allowing doctors to measure exactly how well the carnitine pumps are working.
How does SPCD affect the body's cells?
In SPCD, the high-speed pump that normally pulls carnitine from the blood into the cells is broken or missing. This prevents organs like the heart and muscles from getting the carnitine they need to burn fats for energy, while the kidneys mistakenly flush carnitine out in the urine.

Questions for Your Doctor

  • • Was my child's newborn screen result influenced by my own carnitine levels? Should I be tested too?
  • • Do the genetic results show 'pathogenic' mutations, or are they 'variants of uncertain significance' (VUS)?
  • • If the genetic testing is inconclusive, should we proceed with a functional fibroblast uptake study (skin biopsy)?
  • • Are my child's acylcarnitine levels also low, or is it only the free carnitine (C0) that is affected?
  • • What is the exact target C0 level you want to see in the blood once treatment starts?

Questions for You

  • • Have any other family members experienced unexplained heart issues or muscle weakness?
  • • Am I (the mother) feeling unusually fatigued or experiencing muscle cramps that I previously dismissed?
  • • Do I have a copy of all the specific lab values and genetic report for my family's medical records?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Structural basis of sodium ion-dependent carnitine transport by OCTN2.

    Davies JS, Zeng YC, Briot C, et al.

    Nature communications 2025; (17(1)):181 doi:10.1038/s41467-025-66867-6.

    PMID: 41318751
  2. 2

    Increased detection of primary carnitine deficiency through second-tier newborn genetic screening.

    Lin Y, Zhang W, Huang C, et al.

    Orphanet journal of rare diseases 2021; (16(1)):149 doi:10.1186/s13023-021-01785-6.

    PMID: 33757571
  3. 3

    Clinical, biochemical, and molecular genetic characteristics of patients with primary carnitine deficiency identified by newborn screening in Shanghai, China.

    Chang S, Yang Y, Xu F, et al.

    Frontiers in genetics 2022; (13()):1062715 doi:10.3389/fgene.2022.1062715.

    PMID: 36568374
  4. 4

    A Rare Treatable Cause of Cardiomyopathy: Primary Carnitine Deficiency.

    Basan H, Azak E, Çetin İİ, et al.

    Molecular syndromology 2024; (15(2)):156-160 doi:10.1159/000534932.

    PMID: 38585546
  5. 5

    Recent advances in drug delivery via the organic cation/carnitine transporter 2 (OCTN2/SLC22A5).

    Kou L, Sun R, Ganapathy V, et al.

    Expert opinion on therapeutic targets 2018; (22(8)):715-726 doi:10.1080/14728222.2018.1502273.

    PMID: 30016594
  6. 6

    SLC22A5 (OCTN2) Carnitine Transporter-Indispensable for Cell Metabolism, a Jekyll and Hyde of Human Cancer.

    Juraszek B, Nałęcz KA

    Molecules (Basel, Switzerland) 2019; (25(1)) doi:10.3390/molecules25010014.

    PMID: 31861504
  7. 7

    Glioma cells survival depends both on fatty acid oxidation and on functional carnitine transport by SLC22A5.

    Juraszek B, Czarnecka-Herok J, Nałęcz KA

    Journal of neurochemistry 2021; (156(5)):642-657 doi:10.1111/jnc.15124.

    PMID: 32654140
  8. 8

    Involvement of impaired carnitine-induced fatty acid oxidation in experimental and human diabetic kidney disease.

    Ito S, Taguchi K, Kodama G, et al.

    JCI insight 2025; (10(13)).

    PMID: 40402578
  9. 9

    Assessment of carnitine excretion and its ratio to plasma free carnitine as a biomarker for primary carnitine deficiency in newborns.

    Crefcoeur LL, Heiner-Fokkema MR, Maase RE, et al.

    JIMD reports 2023; (64(1)):57-64 doi:10.1002/jmd2.12334.

    PMID: 36636597
  10. 10

    Incorporating Next-Generation Sequencing as a Second-Tier Test for Primary Carnitine Deficiency.

    Lin Y, Zheng Z, Lin W, Peng W

    Molecular genetics & genomic medicine 2024; (12(9)):e70003 doi:10.1002/mgg3.70003.

    PMID: 39248612
  11. 11

    Biochemical characteristics of newborns with carnitine transporter defect identified by newborn screening in California.

    Gallant NM, Leydiker K, Wilnai Y, et al.

    Molecular genetics and metabolism 2017; (122(3)):76-84 doi:10.1016/j.ymgme.2017.06.015.

    PMID: 28711408
  12. 12

    Carnitine transport and fatty acid oxidation.

    Longo N, Frigeni M, Pasquali M

    Biochimica et biophysica acta 2016; (1863(10)):2422-35.

    PMID: 26828774
  13. 13

    A newborn with seizures born to a mother diagnosed with primary carnitine deficiency.

    Chen S, Hu Y, Huang Y, et al.

    BMC pediatrics 2019; (19(1)):79 doi:10.1186/s12887-019-1452-4.

    PMID: 30885166
  14. 14

    Primary carnitine deficiency: Estimation of prevalence in Chinese population and insights into newborn screening.

    Ji X, Ge Y, Ni Q, et al.

    Frontiers in genetics 2023; (14()):1304458 doi:10.3389/fgene.2023.1304458.

    PMID: 38125748
  15. 15

    Phenotypic and molecular features of Thai patients with primary carnitine deficiency.

    Liammongkolkul S, Boonyawat B, Vijarnsorn C, et al.

    Pediatrics international : official journal of the Japan Pediatric Society 2023; (65(1)):e15404 doi:10.1111/ped.15404.

    PMID: 36321377
  16. 16

    Low serum carnitine level is associated with increased urinary carnitine excretion in late pregnancy.

    Kobori Y, Hirayama S, Fukushima Y, et al.

    Annals of clinical biochemistry 2024; (61(5)):356-364 doi:10.1177/00045632241239806.

    PMID: 38428946
  17. 17

    Maternal Primary Carnitine Deficiency and a Novel Solute Carrier Family 22 Member 5 (SLC22A5) Mutation.

    Jakoby M, Jaju A, Marsh A, Wilber A

    Journal of investigative medicine high impact case reports 2021; (9()):23247096211019543 doi:10.1177/23247096211019543.

    PMID: 34032155
  18. 18

    Biochemical, Molecular, and Clinical Characterization of Patients With Primary Carnitine Deficiency via Large-Scale Newborn Screening in Xuzhou Area.

    Zhou W, Li H, Huang T, et al.

    Frontiers in pediatrics 2019; (7()):50 doi:10.3389/fped.2019.00050.

    PMID: 30863740
  19. 19

    Identification of SLC22A5 Gene Mutation in a Family with Carnitine Uptake Defect.

    Mutlu-Albayrak H, Bene J, Oflaz MB, et al.

    Case reports in genetics 2015; (2015()):259627 doi:10.1155/2015/259627.

    PMID: 26075114
  20. 20

    Functional and molecular studies in primary carnitine deficiency.

    Frigeni M, Balakrishnan B, Yin X, et al.

    Human mutation 2017; (38(12)):1684-1699 doi:10.1002/humu.23315.

    PMID: 28841266
  21. 21

    The Human OCTN Sub-Family: Gene and Protein Structure, Expression, and Regulation.

    Galluccio M, Tripicchio M, Pochini L

    International journal of molecular sciences 2024; (25(16)) doi:10.3390/ijms25168743.

    PMID: 39201429
  22. 22

    Functional genomics of OCTN2 variants informs protein-specific variant effect predictor for Carnitine Transporter Deficiency.

    Koleske ML, McInnes G, Brown JEH, et al.

    Proceedings of the National Academy of Sciences of the United States of America 2022; (119(46)):e2210247119 doi:10.1073/pnas.2210247119.

    PMID: 36343260
  23. 23

    Analysis of genetic mutation distribution and metabolic characteristics in patients with primary carnitine deficiency from the Ganzhou area, China.

    Tu X, Zhang F, Chen J, Xie C

    Clinica chimica acta; international journal of clinical chemistry 2026; (584()):120873 doi:10.1016/j.cca.2026.120873.

    PMID: 41620002

This page explains the diagnostic process and genetics of Systemic Primary Carnitine Deficiency (SPCD) for educational purposes. Always consult a pediatric geneticist or your healthcare provider to interpret specific newborn screening results and genetic tests.

Stay up to date

Get notified when new research about Systemic primary carnitine deficiency is published.

No spam. Unsubscribe anytime.